From virotherapy to oncolytic immunotherapy: Where are we now?

Current Opinion in Virology

Volumn 13, Issue , 2015, Pages 93-100

  Coffin, Robert S ^a  

^a Research Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESEARCH; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; VIRUS REPLICATION; ANIMAL; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PHYSIOLOGY; VIROLOGY;

ANIMALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84933526132     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2015.06.005     Document Type: Review

References (28)

1. T. Mineta, S.D. Rabkin, T. Yazaki, W.D. Hunter, and R.L. Martuza Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas Nat Med 1 1995 938 943
2. J.R. Bischoff, D.H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J.A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 1996 373 376
3. E.A. McKie, A.R. MacLean, A.D. Lewis, G. Cruickshank, R. Rampling, S.C. Barnett, P.G. Kennedy, and S.M. Brown Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours - evaluation of a potentially effective clinical therapy Br J Cancer 74 1996 745 752
4. R. Rampling, G. Cruickshank, V. Papanastassiou, J. Nicoll, D. Hadley, D. Brennan, R. Petty, A. MacLean, J. Harland, E. McKie, R. Mabbs, and M. Brown Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma Gene Ther 7 2000 859 866
5. S. Harrow, V. Papanastassiou, J. Harland, R. Mabbs, R. Petty, M. Fraser, D. Hadley, J. Patterson, S.M. Brown, and R. Rampling HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival Gene Ther 11 2004 1648 1658
6. J.M. Markert, M.D. Medlock, S.D. Rabkin, G.Y. Gillespie, T. Todo, W.D. Hunter, C.A. Palmer, F. Feigenbaum, C. Tornatore, F. Tufaro, and R.L. Martuza Conditionally replicating herpes simplex virus mutant G207 for the treatment of malignant glioma: results of a phase I trial Gene Ther 7 2000 867 874
7. D. Kirn Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials Expert Opin Biol Ther 1 2001 525 538
8. S.K. Geevarghese, D.A. Geller, H.A. de Haan, M. Horer, A.E. Knoll, A. Mescheder, T.R. Reid, D.Y. Sze, K.K. Tanabe, and H. Tawfik Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver Hum Gene Ther 21 2010 1119 1128
9. T.R. Reid, S. Freeman, L. Post, F. McCormick, and D.Y. Sze Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin Cancer Gene Ther 12 2005 673 681
10. A. Snyder, V. Makarov, T. Merghoub, J. Yuan, J.M. Zaretsky, A. Desrichard, L.A. Walsh, M.A. Postow, P. Wong, T.S. Ho, and T.J. Hollmann Genetic basis for clinical response to CTLA-4 blockade in melanoma N Engl J Med 371 2014 2189 2199
11. T.F. Gajewski, H. Schreiber, and Y.X. Fu Innate and adaptive immune cells in the tumor microenvironment Nat Immunol 14 2013 1014 1022
12. R.H. Andtbacka, B. Curti, H. Kaufman, G.A. Daniels, L.E. Spitler, J. Lutzky, S. Hallmeyer, E.D. Whitman, J.J. Nemunaitis, K. Zhou, R. Karpathy, J.I. Weisberg, and D. Shafren CALM study: a phase II study of an intratumorally delivered oncolytic immunotherapeutic agent Coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma ASCO Annual Meeting 2014 abstract 3031
13. R.H. Andtbacka, H.L. Kaufman, F. Collichio, T. Amatruda, N. Senzer, J. Chesney, K.A. Delman, L.E. Spitler, I. Puzanov, S.S. Agarwala, and M. Milhem Talimogene laherparepvec improves durable response rate in patients with advanced melanoma J Clin Oncol 2015 10.1200/JCO.2014.58.3377 (epub ahead of print)
14. K.J. Harrington, M. Hingorani, M.A. Tanay, J. Hickey, S.A. Bhide, P.M. Clarke, L.C. Renouf, K. Thway, A. Sibtain, I.A. McNeish, K.L. Newbold, H. Goldsweig, R. Coffin, and C.M. Nutting Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck Clin Cancer Res 16 2010 4005 4015
15. J. Heo, T. Reid, L. Ruo, C.J. Breitbach, S. Rose, M. Bloomston, M. Cho, H.Y. Lim, H.C. Chung, C.W. Kim, and J. Burke Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Nat Med 19 2013 329 336
16. J.M. Burke, D.L. Lamm, M.V. Meng, J.J. Nemunaitis, J.J. Stephenson, J.C. Arseneau, J. Aimi, S. Lerner, A.W. Yeung, T. Kazarian, D.J. Maslyar, and J.M. McKiernan A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer J Urol 188 2012 2391 2397
17. S.J. Russell, M.J. Federspiel, K.W. Peng, C. Tong, D. Dingli, W.G. Morice, V. Lowe, M.K. O'Connor, R.A. Kyle, N. Leung, and F.K. Buadi Remission of disseminated cancer after systemic oncolytic virotherapy Mayo Clin Proc 89 2014 926 933
18. M.J. Burke, C. Ahern, B.J. Weigel, J.T. Poirier, C.M. Rudin, Y. Chen, T.P. Cripe, M.B. Bernhardt, and S.M. Blaney Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group Pediatr Blood Cancer 62 2015 743 750
19. Oncolytics Biotech press release 16th Sept 2014.
20. V. Boni, F. De La Portilla, A. Cubillo, M. Gil-Martin, E. Calvo, R. Salazar, C. Santos, A. Sanchez-Gastaldo, S. Prados, X. Sanjuan, and J.M. Bozada A phase 1 mechanism of action study of intra-tumoural (IT) or intravenous (IV) administration of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus in colon cancer patients undergoing resection of primary tumour ESMO Annual Meeting 2014 abstract 1068P
21. A. Muik, L.J. Stubbert, R.Z. Jahedi, Y. Gei J. Kimpel, C. Dold, R. Tober, A. Volk, S. Klein, U. Dietrich, and B. Yadollahi Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency Cancer Res 74 2014 3567 3578
22. P. Sharma, and J.P. Allison The future of immune checkpoint therapy Science 348 2015 56 61
23. D. Shafren, M. Quah, Y. Wong, R.H. Andtbacka, and G. Au Combination of a novel oncolytic immunotherapeutic agent, coxsackievirus A21 and PD-1 blockade significantly reduces tumor growth and improves survival in an immune competent mouse melanoma model ESMO Annual Meeting 2014 abstract 1066P
24. P. Piasecki, L. Tiep, R. Ponce, and C. Beers Talilmogene laherparepvec increases the anti-tumor efficacy of the anti-PD-1 immune checkpoint blockade AACR Annual Meeting 2015 abstract 258
25. D. Zamarin, R.B. Holmgaard, S.K. Subudhi, J.S. Park, M. Mansour, P. Palese, T. Merghoub, J.D. Wolchok, and J.P. Allison Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy Sci Trans Med 2014 10.1126/scitranslmed.3008095
26. I. Puzanov, M. Milhem, R.H. Andtbacka, D. Minor, O. Hamid, A. Li, M. Chastain, K. Gorski, A. Anderson, A. VanderWalde, J. Chou, and H. Kaufman Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma ASCO Annual Meeting 2014 abstract 9029
27. NCT01740297 www.clinicaltrials.gov.
28. NCT02263508 www.clinicaltrials.gov.